News

UPAY Inc. Welcomes Richard K. Pellerin to Its Board of Directors

UPAY Inc. Welcomes Richard K. Pellerin to Its Board of Directors

UPAY Inc. Welcomes Richard K. Pellerin to Its Board of Directors

UPAY Inc. (OTCQB: UPYY), a prominent player in the financial technology arena, is enthusiastic to announce a significant new addition to its governance team. The company has appointed Richard K. Pellerin as a Director. This strategic move is set to leverage Mr. Pellerin's extensive experience and innovative insights, marking an exciting period for the company.

About Richard K. Pellerin's Experience

Mr. Pellerin brings over 25 years of robust entrepreneurial, governance, and leadership experience, making him a significant asset to UPAY. He is the Founder and President of Century Rehabilitation, Inc., a company renown for providing therapy, recruitment, and consulting services to skilled nursing and post-acute care facilities. Under his guidance since its founding in 1999, Century Rehabilitation has substantially navigated through industry transitions and has been recognized for its innovative approaches to workforce and technological solutions.

The Impact of Digital Transformation

In addition to his role at Century Rehabilitation, Mr. Pellerin is the Co-Founder of DisruptREADY, an advisory firm specializing in AI and digital transformation. This firm has successfully aided over 150 organizations to integrate and expand their use of artificial intelligence for improved performance and efficiency. His wealth of knowledge in healthcare operations and digital transformation will be influential in bolstering UPAY's growth strategy in the fintech landscape.

Strategic Partnership and Investment

Prior to his recent appointment, Mr. Pellerin exhibited confidence in UPAY's vision by making an investment in the company. This move not only demonstrates his belief in UPAY's strategy and leadership but also his commitment to the company’s long-term growth prospects.

Rich Leadership Contributions

Mr. Pellerin's extensive governance experience is complemented by his philanthropic endeavors. He sits on the Board of the Our Lady of the Lake Foundation, serves in advisory roles at Louisiana State University (LSU), and has made significant contributions through the Richard & Lori Pellerin Athletic Training Suite. Additionally, he has initiated the Century Scholarship Fund to further support educational opportunities.

Statements from UPAY Leadership

Jaco Fölscher, CEO of UPAY, Inc., expressed:
"We are thrilled to have Richard as part of our Board of Directors. His extensive leadership background and expertise in healthcare, digital transformation, and workforce development perfectly align with UPAY's commitment to innovation and sustainable development. Richard's appointment, coupled with his investment in UPAY, reinforces our shared vision for the future growth of the company."

Continued Commitment to Talent and Leadership

The enthusiastic welcome of Mr. Pellerin signifies UPAY's ongoing dedication to attracting high-caliber leaders with diverse backgrounds and expertise, highlighting their strategic objectives and long-term commitment to enhancing shareholder value.

About UPAY Inc.

UPAY Inc. is a U.S. publicly listed fintech holding company that focuses on providing intelligent financial platforms and regulatory compliance technologies across both new and established markets. Their innovative solutions encompass automation, payments, credit-related services, and regulatory advancements. For further information, please visit www.upaytechnology.com.

Frequently Asked Questions

What is the role of Richard K. Pellerin at UPAY?

Richard K. Pellerin has been appointed as a Director of UPAY, utilizing his extensive experience in healthcare and technology.

What prior experience does Mr. Pellerin bring?

Mr. Pellerin has over 25 years of experience and is the Founder and President of Century Rehabilitation, offering therapy and consulting services.

What investment has Mr. Pellerin made in UPAY?

Before his appointment, Mr. Pellerin invested in UPAY, demonstrating his confidence in the company’s vision and growth potential.

What areas will Mr. Pellerin focus on at UPAY?

He will focus on healthcare operations, digital transformation, and workforce management to enhance UPAY’s strategic initiatives.

What are UPAY's main business areas?

UPAY specializes in fintech solutions that include payment processing, credit services, and compliance technologies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading